Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aktis Oncology, Inc. - Common stock (NQ:AKTS)

20.46 +1.34 (+7.01%)
Streaming Delayed Price Updated: 2:05 PM EDT, May 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 76,054
Open 19.46
Bid (Size) 20.25 (100)
Ask (Size) 20.46 (200)
Prev. Close 19.12
Today's Range 19.20 - 20.46
52wk Range 14.72 - 29.16
Shares Outstanding 51,310,014
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company ↗
This clinical-stage biotech develops targeted radiopharmaceutical therapies for cancer using a proprietary miniprotein platform. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance

Performance

YTD
-8.7%
-8.7%
1 Month
-0.2%
-0.2%
3 Month
+11.1%
+11.1%
6 Month
-8.7%
-8.7%
1 Year
-8.7%
-8.7%

More News

Read More
News headline image
Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Aktis Oncology to Present at the BofA Securities Health Care Conference
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Aktis Oncology to Present at Upcoming March Investor Conferences
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market
Via MarketMinute
Topics Artificial Intelligence ETFs Initial Public Offering
MarketBeat Week in Review – 01/12 - 01/16 ↗
Via MarketBeat
News headline image
A Fresh IPO That Long-Term Investors Shouldn’t Ignore ↗
Via MarketBeat
Topics Initial Public Offering
News headline image
Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Aktis Oncology Inc.
Via GlobeNewswire
News headline image
12 Information Technology Stocks Moving In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Crude Oil Down 1%; Webuy Global Shares Spike Higher ↗
Via Benzinga
News headline image
Nasdaq Surges Over 100 Points; NY Empire State Manufacturing Index Dips In December ↗
Via Benzinga
News headline image
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
Akoustis to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
From Akoustis, Inc.
Via GlobeNewswire
News headline image
Akoustis to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
From Akoustis, Inc.
Via Business Wire
News headline image
12 Information Technology Stocks Moving In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Why Uxin Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
12 Information Technology Stocks Moving In Friday's Pre-Market Session ↗
Via Benzinga
News headline image
12 Information Technology Stocks Moving In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
12 Information Technology Stocks Moving In Monday's After-Market Session ↗
Via Benzinga

Frequently Asked Questions

Is Aktis Oncology, Inc. - Common stock publicly traded?
Yes, Aktis Oncology, Inc. - Common stock is publicly traded.
What exchange does Aktis Oncology, Inc. - Common stock trade on?
Aktis Oncology, Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aktis Oncology, Inc. - Common stock?
The ticker symbol for Aktis Oncology, Inc. - Common stock is AKTS on the Nasdaq Stock Market
What is the current price of Aktis Oncology, Inc. - Common stock?
The current price of Aktis Oncology, Inc. - Common stock is 20.46
When was Aktis Oncology, Inc. - Common stock last traded?
The last trade of Aktis Oncology, Inc. - Common stock was at 05/22/26 02:05 PM ET
What is the market capitalization of Aktis Oncology, Inc. - Common stock?
The market capitalization of Aktis Oncology, Inc. - Common stock is 1.05B
How many shares of Aktis Oncology, Inc. - Common stock are outstanding?
Aktis Oncology, Inc. - Common stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.